A randomized double-blind trial showed no effect of a recombinant-engineered human TNF-α-neutralizing antibody (CDP571) compared to placebo on glucose homeostasis in obese T2D patients after 4 weeks [65]. Here, TNF is linked to type 2 diabetes mellitus.